Document Detail


The novel PI3K-mTOR inhibitor, BEZ235, circumvents erlotinib- resistance of EGFR mutant lung cancer cells triggered by HGF.
MedLine Citation:
PMID:  23319394     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a critical problem in the management of patients with EGFR mutant lung cancer. Several mechanisms have been reported involved in this acquired resistance, including hepatocyte growth factor (HGF) activation of an alternative pathway. PI3K and mTOR are downstream molecules of receptor tyrosine kinases, such as EGFR and Met, and are thought to be ideal targets for controlling various tumor types. We assessed whether BEZ235, a dual inhibitor of PI3K and mTOR, could overcome the EGFR-TKI resistance induced by HGF in an EGFR mutant lung cancer model. Exogenous and endogenous HGF triggered resistance to erlotinib in the PC-9 and HCC827, EGFR mutant lung cancer cell lines. BEZ235 alone inhibited the viability of PC-9 and HCC827 cells in vitro, irrespective of the presence or absence of HGF. Using a xenograft model of SCID mice with HGF-gene transfected PC-9 cells (PC-9/HGF), we found that BEZ235 inhibited tumor growth, whereas erlotinib did not. BEZ235 monotherapy also inhibited the phosphorylation of Akt and p70S6K/S6RP, downstream molecules of PI3K and mTOR, respectively, as well as suppressing tumor-cell proliferation and angiogenesis of PC-9/HGF tumors. These results suggest that BEZ235, even as monotherapy, may be useful in managing HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. © 2013 Wiley Periodicals, Inc.
Authors:
Takako Sano; Shinji Takeuchi; Takayuki Nakagawa; Daisuke Ishikawa; Shigeki Nanjo; Tadaaki Yamada; Takahiro Nakamura; Kunio Matsumoto; Seiji Yano
Related Documents :
22986464 - O6-methylguanine-dna methyltransferase is a novel negative effector of invasion in glio...
23834814 - Anterior gradient 2: a novel sensitive tumor marker for metastatic oral cancer.
20813304 - Melanotic neuroectodermal tumor of infancy: report of one calvarial lesion with t1 shor...
12891514 - Tumoral calcinosis of the gluteal region in a child: case report with overview of diffe...
11886524 - Parp determines the mode of cell death in skin fibroblasts, but not keratinocytes, expo...
8657174 - Analysis of national toxicology program rodent bioassay data for anticarcinogenic effects.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-15
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 UICC.
Affiliation:
Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A family genetic risk communication framework: guiding tool development in genetics health services.
Next Document:  Resection for Hilar Cholangiocarcinoma: Analysis of Prognostic Factors and the Impact of Systemic In...